Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 7/20 | 0.47 |
| ▸ | CTSL | P07711 | 6/20 | 0.46 |
| ▸ | CTSS | P25774 | 5/20 | 0.46 |
| ▸ | CTSB | P07858 | 4/20 | 0.46 |
| ▸ | CASP1 | P29466 | 2/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | BACE1 | P56817 | 1/20 | 0.42 |
| ▸ | CTSV | O60911 | 2/20 | 0.42 |
| ▸ | FNTA | P49354 | 3/20 | 0.41 |
| ▸ | FNTB | P49356 | 3/20 | 0.41 |
| ▸ | PGGT1B | P53609 | 3/20 | 0.41 |
| ▸ | CNR2 | P34972 | 2/20 | 0.39 |
| ▸ | CASP3 | P42574 | 1/20 | 0.38 |
| ▸ | CASP7 | P55210 | 1/20 | 0.38 |
| ▸ | CASP6 | P55212 | 1/20 | 0.38 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6664972 | 0.90 | CTSK (0.43) | CTSKCTSLCTSSCTSBCASP1 | |
| SCHEMBL7464820 | 0.89 | CTSL (0.47) | CTSKCTSLCTSSCTSBATM | |
| SCHEMBL7463889 | 0.88 | CTSL (0.49) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL7462272 | 0.87 | CTSL (0.50) | CTSKCTSLCTSSCTSBCASP1 | |
| SCHEMBL6927425 | 0.87 | CTSL (0.55) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL7468998 | 0.86 | CTSK (0.65) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL7467469 | 0.85 | CTSL (0.47) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL7467592 | 0.85 | TAS1R3 (0.49) | CTSKCTSLCTSSCTSBCNR2 | |
| SCHEMBL7473345 | 0.85 | TAS1R3 (0.54) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL6623442 | 0.85 | CTSS (0.51) | CTSKCTSLCTSSCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0983228-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2002-08-07 | — | — | EP | claimed |
| US-20020065230-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-05-30 | — | — | US | claimed |
| EP-0983228-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-03-08 | — | — | EP | claimed |
| WO-1998050342-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-11-12 | — | — | WO | claimed |
| EP-1242404-A1 | PHENOXYPROPANOLAMINES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-SYNTHELABO (FR) | 2002-09-25 | — | — | EP | disclosed |
| EP-0983228-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2002-08-07 | — | — | EP | disclosed |
| US-20020065230-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-05-30 | — | — | US | disclosed |
| WO-2001044227-A1 | PHENOXYPROPANOLAMINES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-SYNTHELABO (FR) | 2001-06-21 | — | — | WO | disclosed |
| EP-0983228-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-03-08 | — | — | EP | disclosed |
| WO-1998050342-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020065230-A1 | Protease inhibitors | PRSS1, DNPEP, CTSZ | CTSK 22/4885CTSL 4/4885CTSS 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.